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Objectives. This study was performed to determine predictors of
subacute stent thrombosis (SST) in the era of intravascular
ultrasound (IVUS)-guided coronary stenting without anticoagula-
tion.
Background. The incidence of stent thrombosis has declined
with the application of high pressure stent deployment with only
antiplatelet therapy. However, no data are available on predictors
of stent thrombosis in this era.
Methods. Between March 30, 1993 and July 31, 1995, 1,042
consecutive patients underwent coronary stenting without antico-
agulation. For this analysis, we excluded patients who underwent
coronary artery bypass surgery, died or had acute stent thrombo-
sis within the 1st 24 h after stenting (41 patients). A total of 1,001
patients (1,334 lesions) were included: 982 patients (1,315 lesions)
without SST and 19 patients (19 lesions) with SST.
Results. The rate of SST was 1.9% (per patient). There was no
difference between the SST and No SST groups in rescue stenting
(12% vs. 13.5%, p5 1.0) or mean6 SD reference diameter (3.116
0.58 vs. 3.19 6 0.53 mm, p 5 0.54). A preexisting thrombus was
present in 12% of the SST group and in 4.5% of the No SST group
(p 5 0.19). Predictors of SST by univariate analysis were low
ejection fraction (p 5 0.004), more stents per lesion (p 5 0.049),
use of combination of different stents (p 5 0.012), smaller balloon
size (p 5 0.012) and suboptimal result in terms of smaller lumen
dimensions by angiography (p 5 0.016) and IVUS (p 5 0.004),
residual dissections (p 5 0.027) and slow flow (p 5 0.0001). In
stepwise logistic regression analysis, ejection fraction (p5 0.019),
use of a combination of different stents (p 5 0.013) and postpro-
cedure dissections (p 5 0.014) and slow flow (p 5 0.0001) were
predictive of SST.
Conclusions. In the present era of stent implantation, factors
that may predispose to SST are low ejection fraction, intraproce-
dural complications leading to utilization of more stents, partic-
ularly with different stent designs, and suboptimal final result in
terms of smaller lumen dimensions and persistent slow flow and
dissections.
(J Am Coll Cardiol 1997;29:6–12)
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Coronary stenting has been shown to reduce the morbidity of
acute vessel closure (1) and to decrease clinical and angio-
graphic restenosis in selected lesions (2,3). However, the rate
of subacute stent thrombosis (SST) and vascular complications
remained high in the era of low pressure stent deployment
despite vigorous anticoagulation (4–6). Intravascular ultra-
sound (IVUS) guidance provided the insight that led to the
application of high pressure stent deployment. These technical
refinements have been shown (7,8) to decrease the rate of SST
despite the use of antiplatelet therapy alone. Although the
incidence of SST is reduced, limited data are available on
predictors of SST with this new approach. This report presents
a retrospective analysis of our experience, using a data base
that was collected prospectively, in an attempt to highlight the
factors associated with SST.
Methods
Study patients. From March 30, 1993 until July 31, 1995,
1,042 consecutive patients underwent intracoronary stenting at
Centro Cuore Columbus Hospital in Milan, Italy. To analyze
factors associated with SST, we excluded 41 patients: 6 patients
(0.6%) who had acute stent thrombosis within 24 h of the index
procedure, 29 patients (2.8%) who underwent coronary artery
bypass surgery (27 emergently and 2 within the 1st 24 h after
stenting) and 6 patients (0.6%) who died during the procedure.
A total of 1,001 patients with 1,334 lesions were included in
this study. Patients were classified into two groups: 982 patients
(1,315 lesions) without SST and 19 patients (19 lesions) with
SST.
Stent implantation procedure. Intracoronary stenting was
performed by using techniques previously described (7–9). The
Palmaz-Schatz coronary stent (Johnson & Johnson Interven-
tional Systems) was the stent most commonly used. Other
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stents included the Gianturco-Roubin Flexstent (Cook Inc.),
the Wiktor stent (Medtronic Interventional Vascular, Kerkrade,
Netherlands), the AVE Micro stent (Applied Vascular Engi-
neering Inc., Richmond, Canada), the Cordis stent (Cordis
Corporation) and the Wallstent (Schneider Europe, Bulach,
Switzerland).
After stent implantation, angiographic optimization was
performed by using high pressure balloon dilation to achieve a
good angiographic result with,20% residual stenosis by visual
estimate. After the angiographic result was considered accept-
able, IVUS studies were performed in 707 patients (72%) in
the No SST group and 13 (68%) in the SST group. Subsequent
treatment decisions were based on IVUS results (when avail-
able) in conjunction with angiographic assessment. The final
IVUS evaluation was the last IVUS study that documented
achievement of optimal stent expansion criteria (9).
Indications for stenting were defined as follows: elective
stenting was performed when the operator elected to use
stenting before starting the procedure; suboptimal result stent-
ing was defined as insertion of a stent for a focal dissection or
significant vascular recoil after percutaneous transluminal cor-
onary angioplasty (PTCA) associated with .30% lumen nar-
rowing without associated ischemia; threatened closure stenting
was performed when PTCA was complicated by a longitudinal
or a spiral dissection associated with .50% lumen encroach-
ment (ischemia was not always present in the setting of
threatened closure); acute occlusion stenting was performed to
relieve ischemia associated with total or subtotal vessel closure
after angioplasty with no or markedly delayed distal flow
(Thrombolysis in Myocardial Infarction [TIMI] grade 0 or 1
flow); total occlusion stenting was performed after reopening a
vessel that had been occluded before the procedure had begun;
restenosis stenting was performed for lesions that recurred $3
months after an angioplasty procedure.
Angiographic analysis. Coronary angiography was per-
formed in a routine manner. Patients received intracoronary
nitroglycerin before initial, final and follow-up angiograms to
achieve maximal vasodilation. Angiographic measurements
were made with the use of digital electronic calipers (Brown
and Sharp) and an optically magnified image in the projection
that demonstrated the tightest stenosis. The guiding catheter
was used as the reference for calibration. Previous studies
(10,11) have shown that measurements obtained with digital
calipers correlate closely with those obtained with computer-
assisted methods, with a low interobserver and intraobserver
variability.
The proximal and distal reference lumen diameters, lesion
minimal lumen diameter and lesion length were measured on
the preintervention film, with the final stent minimal lumen
diameter measured on the final images. The mean reference
lumen diameter was calculated as the average of the proximal
and distal lumen diameters, and the percent diameter stenosis
was calculated as the mean reference lumen diameter minus
the minimal lumen diameter divided by the mean reference
lumen diameter. The reference lumen diameters and minimal
lumen diameter were measured during follow-up angiography,
when similar calculations were performed.
Lesions were characterized according to the modified
American College of Cardiology–American Heart Association
(ACC–AHA) classification (12). Thrombus was defined as a
filling defect seen in multiple projections surrounded by con-
trast medium. Angiographic findings such as the occurrence of
dissection, vessel rupture or side branch compromise were
recorded.
IVUS equipment and measurements. From March 1993
until November 1993, coronary arteries were imaged with a
3.9F monorail system with a 25-MHz transducer-tipped cath-
eter (Interpret Catheter, InterTherapy/CVIS). A Cardiovascu-
lar Imaging System (CVIS) with a 2.9F catheter was used after
November 1993. Validation of quantitative measurements and
pathologic correlation with ultrasound measurements has been
reported (13,14). Images were initially obtained with a manual
pullback system, but starting in July 1994 a mechanical pull-
back device at a speed of 0.5 mm/s was always employed. The
position of the catheter on fluoroscopy was used to correlate
the ultrasound image with the angiogram. The ultrasound
catheter was advanced distal to the stent, and images were
recorded while the imaging catheter was pulled back. On-line
quantitative measurements were performed during the proce-
dure.
Lumen and vessel cross-sectional areas were measured with
the use of a trackball to outline the lumen-intimal interface
and the media-adventitia interface, respectively. The part of
the lesion with the smallest lumen area was selected for
measurements for each pass of the IVUS catheter. Reference
lumen cross-sectional areas were measured proximal and distal
to the stented segments in the closest most normal-appearing
segments. The average reference vessel and lumen cross-
sectional areas were calculated as the average of the proximal
and distal reference vessel and lumen cross-sectional areas.
Interobserver and intraobserver reproducibility of minimal
lumen diameter and lumen cross-sectional area measurements
have already been documented (15).
Definitions. Angiographic success was defined as a final
angiographic residual diameter stenosis of ,20% by visual
estimate. Clinical events were defined as death, coronary artery
bypass surgery, myocardial infarction (Q wave or non-Q wave),
repeat angioplasty and vascular complications. Death was
defined as any death irrespective of cause. However, only
deaths occurring .24 h after stenting are included. A Q wave
Abbreviations and Acronyms
ACC–AHA 5 American College of Cardiology–
American Heart Association
IVUS 5 intravascular ultrasound
PTCA 5 percutaneous transluminal coronary
angioplasty
SST 5 subacute stent thrombosis
TIMI 5 Thrombolysis in Myocardial Infarction
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myocardial infarction was diagnosed when there were docu-
mented new pathologic Q waves (.0.4 s) on an electrocardio-
gram in conjunction with elevation in creatine kinase levels to
greater than twice the upper limit of normal. A non-Q wave
myocardial infarction was diagnosed when an elevation of the
cardiac enzymes to greater than twice the upper limit of
normal was documented without the development of new
pathologic Q waves. Coronary artery bypass surgery was defined
as coronary bypass surgery occurring at $24 h after successful
stenting. Acute thrombosis events were angiographic stent
thrombosis occurring within 24 h of the procedure; those
events were excluded from analysis because of the intent of this
study. SST events were angiographically documented occlu-
sions with TIMI grade 0 or 1 flow at the stent site occurring
.24 h after the stent procedure, or sudden death occurring
within 1 month after the procedure. Repeat angioplasty was
nonemergency angioplasty performed for symptomatic resten-
osis. Vascular complications were defined as the occurrence of
psuedoaneurysm, bleeding or hematoma formation at the
access site requiring transfusion, vascular repair or external
compression. Events in the two patient groups were compared
at the end of 1 month.
Postprocedure management and follow-up. Starting on the
day of the procedure all patients received aspirin, 325 mg/day
indefinitely, but they did not receive dextran or dipyridamole.
The general guidelines were that if the IVUS criteria for
optimal stent expansion were met and the angiographic result
was also acceptable, no further heparin was administered at
the end of the procedure and sheaths were removed within 4 to
6 h. Patients with a final unsuccessful angiographic result
received warfarin on the day of the procedure, and both
heparin and warfarin were continued until the prothrombin
time was.16 s (international normalized ratio 2.0 to 3.5), after
which the heparin was stopped and warfarin continued for 1
month. After a successful procedure, patients were treated
with antiplatelet agents alone (952 patients) (aspirin,
325 mg/day, either alone [253 patients] or in combination with
ticlopidine, 250 mg orally twice daily for 1 month [699 pa-
tients]). The choice of antiplatelet regimen went through
several phases during this study. We started our experience
with stenting without anticoagulation by using a combination
of aspirin and ticlopidine; because of encouraging results after
an 8-month experience with this regimen we started using
aspirin alone in all patients (150 patients). This phase was
followed by a randomized trial of aspirin alone versus aspirin
plus ticlopidine, during which an additional 103 patients re-
ceived aspirin alone. After the end of this trial, all patients
were given a combination of aspirin and ticlopidine.
One month follow-up was performed in all patients by an
interview or a telephone conversation with the patient or the
referring physician.
Statistical analysis. Data were analyzed with the SAS
statistical software package. The patient was used as the unit
for analysis. Categoric variables are presented as mean value6
SD. Differences between groups were evaluated by chi-square
analysis or Fisher exact test for categoric variables and Student
t test for continuous variables. Correlation between indepen-
dent and dependent continuous variables was evaluated by
simple linear regression analysis. The contribution of clinical,
angiographic and procedural variables to the categoric out-
come variable (stent thrombosis) was evaluated with logistic
regression analysis. First, univariate analysis was performed to
evaluate the contribution of each relevant variable indepen-
dently; then variables that were found to be significant in
univariate analysis were entered into a stepwise logistic regres-
sion model where selection of variables was achieved in a
stepwise fashion. Probability values , 0.05 were considered
significant.
Results
Incidence of SST. SST occurred in 19 patients (1.9%) at a
mean postprocedure interval of 9 6 7 days (range 3 to 27). It
was angiographically documented in 17 patients; in the other 2
patients, who died suddenly within 3 weeks of undergoing
multivessel stenting, the cause of death was assumed to be SST.
Because there was no angiographic documentation of the
precise vessel that thrombosed, procedural, angiographic and
IVUS data in these two patients were not included in the
analysis.
Patient characteristics and indications for stenting. The
clinical characteristics of the two subgroups are shown in Table
1. There was no difference in age, gender, frequency of
multivessel disease and unstable angina. However, the SST
group had a lower ejection fraction (57 6 11% vs. 49 6 15%,
p 5 0.002), greater frequency of ejection fraction ,45% (11%
vs. 38%, p5 0.0005) and greater frequency of prior myocardial
infarction (55% vs. 89%, p 5 0.002) than did the No SST
group.
There was no difference in indications for stenting between
the No SST and SST groups. Elective stenting was performed
in 539 patients (55%) in the No SST group versus 10 (58%) in
the SST group (p 5 0.94), stenting after suboptimal PTCA
in 88 patients (9%) versus 3 (18%) (p 5 0.20), bailout stenting
in 132 patients (13.5%) versus 2 (12%) (p5 1.0), stenting after
recanalization of total occlusion in 100 patients (10%) versus 2
(12%) (p 5 0.69), stenting for restenosis in 118 patients (12%)









Age (yr) 58 6 9 58 6 9 1.0
Male 860 (88%) 17 (89%) 0.57
Previous myocardial infarction 536 (55%) 17 (89%) 0.002
LVEF (%) 57 6 11 49 6 15 0.002
Unstable angina* 193 (20%) 6 (32%) 0.19
Multivessel disease 485 (49%) 10 (53%) 0.78
*Canadian Cardiovascular Society angina classification. Data presented are
mean value 6 SD. LVEF 5 left ventricular ejection fraction; SST 5 subacute
stent thrombosis.
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versus 0 (0%) (p 5 0.25) and stenting in the setting of acute
myocardial infarction in 5 patients (0.5%) versus 0 (0%) (p 5
1.0).
Angiographic and procedural characteristics. Baseline an-
giographic characteristics are shown in Table 2. There was no
difference in lesion location or complexity between groups.
Thrombus was present in 45 patients (4.6%) in the No SST
group versus 2 patients (12%) in the SST group (p 5 0.19).
Procedural characteristics are shown in Table 3. The ma-
jority of stents used in this study were Palmaz-Schatz stents. A
combination of different stent types was used in 69 patients
(7%) in the No SST group versus 4 (24%) in the SST group
(p 5 0.03). Postprocedure residual dissections were present in
25 patients (2.5%) in the No SST group versus 2 (12%) in the
SST group (p 5 0.07) and slow flow was present in 3 patients
in each group (0.3% vs. 18%, p , 0.0001). These markers of a
suboptimal result persisted despite the use of more stents in an
attempt to correct the problem. Multiple stents were used in
412 patients (42%) in the No SST group versus 11 (65%) in the
SST group (p 5 0.10).
Quantitative angiographic and IVUS analysis. Quantita-
tive angiographic data are shown in Table 4. There was no
difference in baseline proximal reference vessel diameter and
lesion length between groups. However, the SST group had a
smaller postprocedure minimal lumen diameter (3.14 6 0.55
vs. 2.82 6 0.48 mm, p 5 0.017) and a higher residual percent
diameter stenosis (21.8 6 14% vs. 5.4 6 16%, p 5 0.036).
IVUS measurements after the stent procedure were avail-
able for 707 patients in the No SST group (72%) and 13 in the
SST group (68%) (p 5 0.93). There was no significant differ-
ence in proximal reference vessel cross-sectional area between
the No SST and SST groups (15.18 6 4.6 mm2 vs. 13.2 6
4.8 mm2, p 5 0.12). However, the SST group had a smaller
postprocedure minimal lumen diameter (2.88 6 0.5 vs. 2.48 6
0.36 mm, p 5 0.004) and smaller lumen cross-sectional area
(7.75 6 2.52 vs. 5.87 6 1.73 mm2, p 5 0.008) measured at the
tightest point within the stent.
Postprocedure pharmacologic therapy and clinical events
at 1 month. A combination of ticlopidine and aspirin was used
in 688 patients (70%) in the No SST group versus 11 (59%) in
the SST group (p 5 0.25). Aspirin alone was used in 245
patients (25%) in the No SST group versus 8 (41%) in the SST
group (p 5 0.09). Forty-nine patients (5%) in the No
SST group received warfarin in comparison with none in the
SST group (p 5 0.38).
All patients had clinical follow-up at 1 month after stenting.
Major clinical events were significantly more frequent in the










LAD 473 (48.5%) 10 (59%) 0.53
LCx 149 (15%) 2 (12%) 1.0
RCA 277 (28%) 4 (23%) 0.79
LMCA 12 (1%) 0 1.0
Intermediate 6 (0.5%) 0 1.0
Diagonal 22 (2%) 1 (6%) 0.33
Obtuse marginal 22 (2%) 0 1.0
SVG 31 (3%) 0 1.0
Lesion site
Ostial 59 (6%) 0 0.62
Proximal 412 (42%) 11 (65%) 0.10
Midvessel 403 (41%) 4 (24%) 0.21
Distal 108 (11%) 2 (12%) 0.71
Thrombus 45 (4.5%) 2 (12%) 0.19
Modified AHA–ACC lesion type
A 69 (7%) 1 (6%) 1.0
B1 344 (35%) 5 (33%) 0.82
B2 393 (40%) 7 (39%) 0.92
C 176 (18%) 4 (22%) 0.53
Data presented are number (%) of patients. AHA–ACC 5 American Heart
Association–American College of Cardiology classification; LAD 5 left anterior
descending coronary artery; LCx5 left circumflex coronary artery; LMCA5 left
main coronary artery; RCA 5 right coronary artery; SST 5 subacute stent
thrombosis; SVG 5 saphenous vein graft.










Palmaz-Schatz 657 (67%) 10 (60%) 0.66
Gianturco-Roubin Flexstent 69 (7%) 0 0.62
Wiktor 74 (7.5%) 1 (6%) 1.0
AVE Micro 29 (3%) 0 1.0
Cordis 20 (2%) 1 (5%) 0.31
Wall 39 (4%) 1 (5%) 0.50
Angio 5 (0.5%) 0 1.0
NIR 20 (2%) 0 1.0
Combination of stents 69 (7%) 4 (24%) 0.03
Stents/lesion 1.5 6 1 2 6 1 0.041
Final balloon size (mm) 3.66 0.5 3.3 6 0.5 0.014
Final B/V ratio 1.146 0.18 1.0 6 0.24 0.001
Maximal inflation pressure (atm) 166 3 17 6 2 0.17
Data presented are mean value 6 SD or number (%) of patients. B/V
ratio 5 balloon diameter divided by proximal reference vessel diameter; SST 5
subacute stent thrombosis.











Reference vessel diameter (mm)* 3.196 0.53 3.11 6 0.58 0.54
Minimal lumen diameter (mm) 0.946 0.56 0.74 6 0.47 0.14
Percent diameter stenosis 696 18 75 6 17 0.17
Lesion length (mm) 10.266 7.0 8.58 6 5.0 0.32
Postprocedure
Stent minimal luman diameter (mm) 3.146 0.55 2.82 6 0.48 0.017
Stent percent diameter stenosis 21.8 6 14 5.4 6 16 0.036
*Proximal vessel diameter. Data presented are mean value 6 SD. SST 5
subacute stent thrombosis.
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SST group. Nonfatal myocardial infarction occurred in 1
patient (0.1%) in the No SST group versus 11 (58%) in the SST
group (p , 0.00001). Coronary artery bypass surgery was
performed in two patients (0.2%) in the No SST group versus
three (16%) in the SST group (p 5 0.00006), and death
occurred in one patient (0.1%) in the No SST group versus five
(26%) in the SST group (p , 0.000001). When all major
clinical events are considered, only four patients (0.4%) in the
No SST group had a major event compared with all patients in
the SST group (p , 0.000001).
Correlates of SST. As shown in Table 5, univariate predic-
tors of SST were low left ventricular ejection fraction, number
of stents per lesion, use of a combination of different stent
types, smaller balloon size, smaller postprocedure angio-
graphic stent minimal lumen diameter and intravascular ultra-
sound stent cross-sectional area and residual dissections and
slow flow. When all these variables were entered into stepwise
logistic regression analysis, four factors predicted stent throm-
bosis: postprocedure slow flow or residual dissections, use of a
combination of different stent types and low baseline left
ventricular ejection fraction.
Discussion
Our findings demonstrate that SST in the era of high
pressure stent optimization without subsequent anticoagula-
tion is a multifactorial process. Clinical factors such as low
ejection fraction and procedural factors such as suboptimal
stent expansion and postprocedure complications leading to
utilization of more stents per lesion without full correction of
the problem, residual postprocedure dissections and slow flow
are the major determinants of subsequent SST.
SST: a multifactorial process frequently procedure related.
Large multicenter studies on patients undergoing elective
stenting in the era of low pressure stent deployment and
anticoagulation reported an incidence rate of stent thrombosis
of 3% to 4% (2–4). When stenting was performed for bailout
or emergency indications, the rate of stent thrombosis in-
creased to 8% to 16% (1,16). In the same period, studies with
the Palmaz-Schatz stent and the Wallstent (4,6,17,18) reported
lesion-related factors predisposing to stent thrombosis includ-
ing tortuous segments, undersizing of stents, intraluminal
filling defects before or after stent implantation, acute ischemic
syndromes, small vessels (,3 mm) and poor distal runoff.
Agrawal et al. (19) reported that factors predisposing to stent
thrombosis after use of the flexible coil stent with anticoagu-
lation were residual dissections, persistent filling defects, small
stent size (,2.5 mm) and multiple stents. Nath et al. (20)
reported that lesion eccentricity, bailout stenting, unstable
angina and subtherapeutic anticoagulation were factors pre-
disposing to stent thrombosis with the coil stent.
Few data are available on clinical and procedural predictors
of stent thrombosis in the era of no anticoagulation and only
antiplatelet therapy. In the present study, proximal reference
diameter was not predictive of stent thrombosis; 344 patients
(35%) in the No SST group and 7 (41%) in the SST group had
a proximal reference vessel diameter ,3.0 mm (p 5 0.78). In
addition, there was no difference in lesion length and complex-
ity (by ACC–AHA classification). There was a trend toward
higher frequency of thrombus at the lesion site in the SST
group (p 5 0.19). There was no difference in stent thrombosis
among the different stents used. However, the power of this
study may be insufficient to evaluate this issue.
In univariate analysis, baseline left ventricular ejection
fraction appeared to be an important clinical predictor of stent
thrombosis, as a lower ejection fraction predicted a higher
probability of stent thrombosis (p 5 0.004). Among intrapro-
cedural factors, the probability of stent thrombosis increased
with the use of more stents per lesion (p 5 0.049), a combi-
nation of different stent types (p 5 0.012) and a smaller
balloon size during final stent optimization (p 5 0.012). The
final stenting result led to an increased probability of stent
thrombosis, when smaller final lumen dimensions were
achieved as measured by angiography (p 5 0.016) or IVUS
Table 5. Correlates of Stent Thrombosis by Logistic Regression Analysis










LVEF 20.053 6 0.019 0.004 20.054 6 0.023 0.019
Procedural
Stent combination 1.46 6 0.582 0.012 1.73 6 0.696 0.013
Balloon size 21.44 6 0.576 0.012 — —
Stents per lesion 0.254 6 0.129 0.049 — —
Postprocedure
Slow flow 4.54 6 0.859 0.0001 5.12 6 1.033 0.0001
Dissections 1.71 6 0.774 0.027 2.33 6 0.945 0.014
Stent MLD (angiographic) 21.09 6 0.458 0.016 — —
Stent MLCSA (IVUS) 20.457 6 0.159 0.004 — —
*p, 0.05 is considered significant. Data presented are mean value6 SD. IVUS5 intravascular ultrasound; LVEF5
left ventricular ejection fraction; MLCSA 5 minimal lumen cross-sectional area; MLD 5 minimal lumen diameter.
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(p 5 0.004) and when slow flow (p 5 0.0001) or residual
dissections (p 5 0.027) persisted after the procedure. In
stepwise logistic regression analysis, four factors remained
significant in predicting a higher probability of stent thrombo-
sis: low ejection fraction (p 5 0.019), use of a combination of
stents (p 5 0.013), postprocedure slow flow (p 5 0.0001) and
dissections (p 5 0.014). However, the use of stepwise regres-
sion analysis with a low event rate can cause important
correlations to drop out in the presence of real or accidental
stronger relations.
One possible explanation for these findings is that more
angiographic complications (dissections, coil stent deformity,
plaque prolapse) occurred at the time of initial stent deploy-
ment in the SST group. Subsequently, more stents (often of
different types) were required in an attempt to correct this
problem. Nevertheless, the final result in this particular group
was frequently suboptimal with a smaller final angiographic
stent minimal lumen diameter (Fig. 1A) and smaller stent
cross-sectional area by IVUS (Fig. 1B). An alternative expla-
nation for the influence of stent combinations on stent throm-
bosis may be that the use of several different stent types may
create a nonlinear flow pattern that increases the propensity
for thrombosis.
The occurrence of unstable angina and bailout stenting did
not predict the risk of SST. This conclusion highlights the
unique importance of the achievement of an optimal final
result. The message is that bailout stenting and stenting for
dissections carry a high risk of SST only when the underlying
angiographic problem is not fully corrected. The final result
remains the common denominator. The only exception to this
statement is the presence of a baseline low ejection fraction,
which may create a slow flow condition that is difficult to
correct by lumen optimization. This setting may require a more
potent antiplatelet regimen to diminish the risk of SST.
Role of IVUS and balloon sizing. IVUS provided informa-
tion regarding the adequacy of stent deployment and reference
vessel dimensions. This information was essential for appro-
priate balloon sizing and for maximizing the probability of
optimal stent expansion. IVUS-guided stenting was used in 13
patients in the SST group; however, final IVUS imaging
documented smaller lumen dimensions in this group than in
the No SST group (Fig. 1B). The other six patients in the SST
group did not have IVUS interrogation; in three of the six, this
lack was due to unavailability of appropriate equipment at the
time of the procedure, and in the other three, procedural
complications made ultrasound interrogation potentially un-
safe. In these six patients, the adequacy of stent deployment
and balloon sizing was determined with angiography. There-
fore, no firm conclusions could be made in regard to the role
of IVUS as such, because this study was not a randomized
comparison between angiography and IVUS guidance of cor-
onary stenting.
Balloons were undersized in the SST group. Five patients
(27%) in this group, had a balloon versus 86 (8.8%) in the No
SST group, vessel ratio ,0.9 (p 5 0.01). This finding is of
critical importance because the balloon/vessel ratio in this
study correlated inversely with postprocedure angiographic
residual percent diameter stenosis (r 5 0.42, coefficient 5
232.67, p 5 0.0001, confidence interval 5 236.76 to 228.57)
(Fig. 2).
Role of antiplatelet therapy. The value of ticlopidine in
diminishing SST is the subject of ongoing clinical trials.
Recently, we (21) reported a randomized comparison between
ticlopidine and aspirin versus aspirin alone after coronary
stenting, with a positive trend favoring the combination of
antiplatelet agents in reducing the rate of stent thrombosis.
The present study cannot provide data to support the superi-
ority of one antiplatelet regimen over the other by virtue of
design and absence of systematic randomization.
Study limitations. Several important limitations should be
noted when interpreting the results of this study. It is a
Figure 1. A, Comparison of the percentile distribution curves for final
angiographic stent minimal lumen diameter (Fin stent MLD) for the
groups with and without subacute stent thrombosis (SST). B, Compar-
ison of the percentile distribution curves for final intravascular ultra-
sound cross-sectional area (Fin IVUS CSA) in the stented segment for
the two groups. Solid circles 5 no SST; open circles 5 SST.
Figure 2. Linear regression analysis of balloon/vessel ratio (B/V) and
final residual angiographic percent diameter stenosis after stenting.
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retrospective analysis; multiple different designs of stents were
used, a situation that does not allow one to draw conclusions
regarding the role of a specific stent design in inducing
thrombosis; the assignment of antiplatelet regimens was not
based on a randomized protocol, thus limiting conclusions in
regard to the best post-stenting pharmacologic regimen. In
addition, because of the low event rate (SST) in this cohort,
two common problems might arise: Chance occurrences may
suggest significant observations, and true relations may not
achieve nominal significance. Therefore, ideally in the present
era of stent implantation, a larger cohort of patients is neces-
sary to determine predictors of SST with high statistical power.
Despite these limitations, this is the first large study to examine
predictors of SST in the era of high pressure stent deployment
without anticoagulation, and it provides a practical insight into
the multifactorial nature of this process.
Conclusions. SST in this era of stent implantation without
subsequent anticoagulation has diminished. However, despite
aggressive management, it is still associated with serious
clinical events. This study has identified several factors that
predispose to SST: low ejection fraction, intraprocedural com-
plications with postprocedure residual dissections or slow flow
leading to a final suboptimal angiographic or IVUS result.
Other adverse factors that may have a role in SST include
preexisting thrombus and use of multiple stents. The role of
different regimens of antiplatelet therapy, including some new,
more specific antiplatelet agents, needs to be further investi-
gated, particularly in high risk groups. In addition, new stent
designs with a higher rate of successful implantation in com-
plex and unfavorable anatomic settings may further decrease
the number of patients who have a final suboptimal result.
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